Invivyd Inc (IVVD)
1.58
-0.12
(-7.06%)
USD |
NASDAQ |
Jun 14, 16:00
1.58
0.00 (0.00%)
After-Hours: 20:00
Invivyd Research and Development Expense (TTM): 162.62M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 162.62M |
| December 31, 2023 | 158.66M |
| September 30, 2023 | 116.31M |
| June 30, 2023 | 120.87M |
| March 31, 2023 | 114.38M |
| December 31, 2022 | 179.21M |
| Date | Value |
|---|---|
| September 30, 2022 | 227.72M |
| June 30, 2022 | 242.96M |
| March 31, 2022 | 240.89M |
| December 31, 2021 | 182.89M |
| September 30, 2021 | 121.72M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
114.38M
Minimum
Mar 2023
242.96M
Maximum
Jun 2022
169.84M
Average
162.62M
Median
Mar 2024
Research and Development Expense (TTM) Benchmarks
| Vanda Pharmaceuticals Inc | 78.74M |
| Viking Therapeutics Inc | 76.90M |
| Stoke Therapeutics Inc | 84.97M |
| 180 Life Sciences Corp | 2.525M |
| MAIA Biotechnology Inc | 11.24M |